Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates

Bioconjugate Chemistry

Volumn 28, Issue 4, 2017, Pages 1102-1114

  Devay, Rachel M ^a,b   Delaria, Kathy ^a   Zhu, Guoyun ^a   Holz, Charles ^a   Foletti, Davide ^a,c   Sutton, Janette ^a   Bolton, Gary ^a   Dushin, Russell ^a   Bee, Christine ^a,e   Pons, Jaume ^a,d   Rajpal, Arvind ^a,e   Liang, Hong ^a,b   Shelton, David ^a   Liu, Shu Hui ^a   Strop, Pavel ^a,e  

^a PFIZER INC   (United States)

^b Kodiak Sciences Inc   (United States)

^c 23andme ^*  (United States)

^d Alexo Therapeutics   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; CELL MEMBRANES; CONTROLLED DRUG DELIVERY; METABOLITES; RECYCLING; TARGETED DRUG DELIVERY;

ANTIBODY-DRUG CONJUGATES; CANCER CELLS; CELL KILLING; CELL SURFACES; CHEMOTHERAPEUTIC AGENTS; IN-VITRO; INTRACELLULAR TRAFFICKING; MODULAR DESIGNS; PROOF OF CONCEPT; VITRO AND IN VIVO;

TOXIC MATERIALS;

ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN APLP2; PROTEIN TROP2; TOXIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; ANTIBODY CONJUGATE; APLP2 PROTEIN, HUMAN; NERVE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL KILLING; CELL MIGRATION; CELL SURFACE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG POTENCY; EC50; ENDOCYTOSIS; ENDOSOME; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LYSOSOME; MCF-7 CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SINGLE DRUG DOSE; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CHEMISTRY; IMMUNOLOGY; METABOLISM; NUDE MOUSE; TRANSCYTOSIS; TUMOR CELL LINE;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; LYSOSOMES; MICE, NUDE; NERVE TISSUE PROTEINS; RECEPTOR, ERBB-2; TRANSCYTOSIS;

EID: 85018520423     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.7b00013     Document Type: Article

References (65)

1. Senter, P. D. and Sievers, E. L. (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 30, 631-7 10.1038/nbt.2289
2. Chari, R. V., Miller, M. L., and Widdison, W. C. (2014) Antibody-drug conjugates: an emerging concept in cancer therapy Angew. Chem., Int. Ed. 53, 3796-827 10.1002/anie.201307628
3. Sievers, E. L. and Senter, P. D. (2013) Antibody-drug conjugates in cancer therapy Annu. Rev. Med. 64, 15-29 10.1146/annurev-med-050311-201823
4. Carter, P. J. and Senter, P. D. (2008) Antibody-drug conjugates for cancer therapy Cancer J. 14, 154-69 10.1097/PPO.0b013e318172d704
5. Senter, P. D. (2009) Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13, 235-44 10.1016/j.cbpa.2009.03.023
6. Lambert, J. M. (2013) Drug-conjugated antibodies for the treatment of cancer Br. J. Clin. Pharmacol. 76, 248-62 10.1111/bcp.12044
7. Panowski, S., Bhakta, S., Raab, H., Polakis, P., and Junutula, J. R. (2014) Site-specific antibody drug conjugates for cancer therapy MAbs 6, 34-45 10.4161/mabs.27022
8. Dosio, F., Brusa, P., and Cattel, L. (2011) Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components Toxins 3, 848-83 10.3390/toxins3070848
9. McCombs, J. R. and Owen, S. C. (2015) Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry AAPS J. 17, 339-51 10.1208/s12248-014-9710-8
10. Shen, B. Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S. F., and Mai, E. et al. 2012, Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 30, 184-9 10.1038/nbt.2108
11. Strop, P., Liu, S. H., Dorywalska, M., Delaria, K., Dushin, R. G., Tran, T. T., Ho, W. H., Farias, S., Casas, M. G., and Abdiche, Y. et al. 2013, Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates Chem. Biol. 20, 161-7 10.1016/j.chembiol.2013.01.010
12. Jain, N., Smith, S. W., Ghone, S., and Tomczuk, B. (2015) Current ADC Linker Chemistry Pharm. Res. 32, 3526-40 10.1007/s11095-015-1657-7
13. Ritchie, M., Tchistiakova, L., and Scott, N. (2013) Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates MAbs 5, 13-21 10.4161/mabs.22854
14. Alley, S. C., Okeley, N. M., Sanderson, R. J., Nanayakkara, V., Campbell, R. L., Kline, T. B., Doronina, S. O., Jeffrey, S. C., Benjamin, D., and Senter, P. D. (2006) Intracellular metabolism of antibody-drug conjugates: identification and quantitation of released drugs Cancer Res. 66, 469-469
15. Shen, B. Q., Bumbaca, D., Saad, O., Yue, Q., Pastuskovas, C. V., Khojasteh, S. C., Tibbitts, J., Kaur, S., Wang, B., and Chu, Y. W. et al. 2012, Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism Curr. Drug Metab. 13, 901-10 10.2174/138920012802138598
16. Strop, P., Delaria, K., Foletti, D., Witt, J. M., Hasa-Moreno, A., Poulsen, K., Casas, M. G., Dorywalska, M., Farias, S., and Pios, A. et al. 2015, Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading Nat. Biotechnol. 33, 694-6 10.1038/nbt.3274
17. Lyon, R. P., Bovee, T. D., Doronina, S. O., Burke, P. J., Hunter, J. H., Neff-LaFord, H. D., Jonas, M., Anderson, M. E., Setter, J. R., and Senter, P. D. (2015) Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index Nat. Biotechnol. 33, 733-5 10.1038/nbt.3212
18. DeVay, R. M., Shelton, D. L., and Liang, H. (2013) Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2) J. Biol. Chem. 288, 10805-18 10.1074/jbc.M113.453373
19. DeVay, R. M., Yamamoto, L., Shelton, D. L., and Liang, H. (2015) Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function PLoS One 10, e0125127 10.1371/journal.pone.0125127
20. Tuli, A., Sharma, M., Capek, H. L., Naslavsky, N., Caplan, S., and Solheim, J. C. (2009) Mechanism for amyloid precursor-like protein 2 enhancement of major histocompatibility complex class I molecule degradation J. Biol. Chem. 284, 34296-307 10.1074/jbc.M109.039727
21. Tuli, A., Sharma, M., McIlhaney, M. M., Talmadge, J. E., Naslavsky, N., Caplan, S., and Solheim, J. C. (2008) Amyloid precursor-like protein 2 increases the endocytosis, instability, and turnover of the H2-K(d) MHC class I molecule J. Immunol. 181, 1978-87 10.4049/jimmunol.181.3.1978
22. Pandey, P., Sliker, B., Peters, H. L., Tuli, A., Herskovitz, J., Smits, K., Purohit, A., Singh, R. K., Dong, J., and Batra, S. K. et al. 2016, Amyloid precursor protein and amyloid precursor-like protein 2 in cancer Oncotarget 15, 19430-19444 10.18632/oncotarget.7103
23. Bertelsen, V. and Stang, E. (2014) The Mysterious Ways of ErbB2/HER2 Trafficking Membranes (Basel, Switz.) 4, 424-46 10.3390/membranes4030424
24. Austin, C. D., De Maziere, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C., Sliwkowski, M. X., Klumperman, J., and Scheller, R. H. (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin Mol. Biol. Cell 15, 5268-82 10.1091/mbc.E04-07-0591
25. Sorkin, A. and Goh, L. K. (2008) Endocytosis and intracellular trafficking of ErbBs Exp. Cell Res. 314, 3093-106
26. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235, 177-82 10.1126/science.3798106
27. Dokter, W., Ubink, R., van der Lee, M., van der Vleuten, M., van Achterberg, T., Jacobs, D., Loosveld, E., van den Dobbelsteen, D., Egging, D., and Mattaar, E. et al. 2014, Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform Mol. Cancer Ther. 13, 2618-29 10.1158/1535-7163.MCT-14-0040-T
28. Girish, S., Gupta, M., Wang, B., Lu, D., Krop, I. E., Vogel, C. L., Burris Iii, H. A., LoRusso, P. M., Yi, J. H., and Saad, O. et al. 2012, Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer Cancer Chemother. Pharmacol. 69, 1229-40 10.1007/s00280-011-1817-3
29. van der Lee, M. M., Groothuis, P. G., Ubink, R., van der Vleuten, M. A., van Achterberg, T. A., Loosveld, E. M., Damming, D., Jacobs, D. C., Rouwette, M., and Egging, D. F. et al. 2015, The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers Mol. Cancer Ther. 14, 692-703 10.1158/1535-7163.MCT-14-0881-T
30. Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D. Y., Dieras, V., and Guardino, E. et al. 2012, Trastuzumab emtansine for HER2-positive advanced breast cancer N. Engl. J. Med. 367, 1783-91 10.1056/NEJMoa1209124
31. Amiri-Kordestani, L., Wedam, S., Zhang, L., Tang, S., Tilley, A., Ibrahim, A., Justice, R., Pazdur, R., and Cortazar, P. (2014) First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer Clin. Cancer Res. 20, 5359-64 10.1158/1078-0432.CCR-14-1268
32. Blumenthal, G. M., Scher, N. S., Cortazar, P., Chattopadhyay, S., Tang, S., Song, P., Liu, Q., Ringgold, K., Pilaro, A. M., and Tilley, A. et al. 2013, First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer Clin. Cancer Res. 19, 4911-6 10.1158/1078-0432.CCR-13-1212
33. Moody, P. R., Sayers, E. J., Magnusson, J. P., Alexander, C., Borri, P., Watson, P., and Jones, A. T. (2015) Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes Mol. Ther. 23, 1888-98 10.1038/mt.2015.178
34. Li, J. Y., Perry, S. R., Muniz-Medina, V., Wang, X., Wetzel, L. K., Rebelatto, M. C., Hinrichs, M. J., Bezabeh, B. Z., Fleming, R. L., and Dimasi, N. et al. 2016, A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy Cancer Cell 29, 117-29 10.1016/j.ccell.2015.12.008
35. Baselga, J. and Albanell, J. (2001) Mechanism of action of anti-HER2 monoclonal antibodies Ann. Oncol 12, S35-41 10.1093/annonc/12.suppl-1.S35
36. Sliwkowski, M. X., Lofgren, J. A., Lewis, G. D., Hotaling, T. E., Fendly, B. M., and Fox, J. A. (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin. Oncol. 26, 60-70
37. Mimnaugh, E. G., Chavany, C., and Neckers, L. (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin J. Biol. Chem. 271, 22796-801 10.1074/jbc.271.37.22796
38. Strop, P., Tran, T., Dorywalska, M., Delaria, K., Dushin, R., Wong, O., Ho, W., Zhou, D., Wu, A., and Kraynov, E. et al. 2016, RN927C, a site-specific Trop-2 antibody-drug-conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models Mol. Cancer Ther. 15, 2698 10.1158/1535-7163.MCT-16-0431
39. Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., Arrojo, R., Liu, D., Rossi, E. A., Chang, C. H., and Goldenberg, D. M. (2015) Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers Bioconjugate Chem. 26, 919-31 10.1021/acs.bioconjchem.5b00223
40. Faltas, B., Goldenberg, D. M., Ocean, A. J., Govindan, S. V., Wilhelm, F., Sharkey, R. M., Hajdenberg, J., Hodes, G., Nanus, D. M., and Tagawa, S. T. (2016) Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma Clin. Genitourin. Cancer 14, e75-9 10.1016/j.clgc.2015.10.002
41. Starodub, A. N., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Jr., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., and Wegener, W. A. et al. 2015, First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors Clin. Cancer Res. 21, 3870-8 10.1158/1078-0432.CCR-14-3321
42. Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., and Zabinski, R. F. et al. 2006, Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity Bioconjugate Chem. 17, 114-24 10.1021/bc0502917
43. Dorywalska, M., Strop, P., Melton-Witt, J. A., Hasa-Moreno, A., Farias, S. E., Galindo Casas, M., Delaria, K., Lui, V., Poulsen, K., and Loo, C. et al. 2015, Effect of attachment site on stability of cleavable antibody drug conjugates Bioconjugate Chem. 26, 650-9 10.1021/bc5005747
44. Dorywalska, M., Strop, P., Melton-Witt, J. A., Hasa-Moreno, A., Farias, S. E., Galindo Casas, M., Delaria, K., Lui, V., Poulsen, K., and Sutton, J. et al. 2015, Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy PLoS One 10, e0132282 10.1371/journal.pone.0132282
45. Miyazaki, K., Kobayashi, M., Natsume, T., Gondo, M., Mikami, T., Sakakibara, K., and Tsukagoshi, S. (1995) Synthesis and antitumor activity of novel dolastatin 10 analogs Chem. Pharm. Bull. 43, 1706-18 10.1248/cpb.43.1706
46. Pettit, G. R., Kamano, Y. K., Herald, C. L., Tuinman, A. A., Boettner, F. E., Kizu, H., Schmidt, J. M., Baczynskyj, L., Tomer, K. B., and Bontems, R. J. (1987) The Isolation and Structure of a Remarkable Marine Animal Antineoplastic Constituent: Dolastatin 10 J. Am. Chem. Soc. 109, 6883-6885 10.1021/ja00256a070
47. Dorywalska, M., Dushin, R., Moine, L., Farias, S. E., Zhou, D., Navaratnam, T., Lui, V., Hasa-Moreno, A., Galindo Casas, M., and Tran, T. T. et al. 2016, Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design Mol. Cancer Ther. 15, 958-970 10.1158/1535-7163.MCT-15-1004
48. Tumey, L. N., Charati, M., He, T., Sousa, E., Ma, D., Han, X., Clark, T., Casavant, J., Loganzo, F., and Barletta, F. et al. 2014, Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy Bioconjugate Chem. 25, 1871-80 10.1021/bc500357n
49. Burke, P. J., Hamilton, J. Z., Pires, T. A., Setter, J. R., Hunter, J. H., Cochran, J. H., Waight, A. B., Gordon, K. A., Toki, B. E., and Emmerton, K. K. et al. 2016, Development of novel quaternary ammonium linkers for antibody-drug conjugates Mol. Cancer Ther. 15, 938-945 10.1158/1535-7163.MCT-16-0038
50. Lyon, R. P., Setter, J. R., Bovee, T. D., Doronina, S. O., Hunter, J. H., Anderson, M. E., Balasubramanian, C. L., Duniho, S. M., Leiske, C. I., and Li, F. et al. 2014, Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates Nat. Biotechnol. 32, 1059-62 10.1038/nbt.2968
51. Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., and Senter, P. D. (2008) Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjugate Chem. 19, 759-65 10.1021/bc7004329
52. Goh, L. K., Huang, F., Kim, W., Gygi, S., and Sorkin, A. (2010) Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor J. Cell Biol. 189, 871-83 10.1083/jcb.201001008
53. Goh, L. K. and Sorkin, A. (2013) Endocytosis of receptor tyrosine kinases Cold Spring Harbor Perspect. Biol. 5, a017459 10.1101/cshperspect.a017459
54. Roskoski, R., Jr. (2014) The ErbB/HER family of protein-tyrosine kinases and cancer Pharmacol. Res. 79, 34-74 10.1016/j.phrs.2013.11.002
55. Strop, P., Ho, W. H., Boustany, L. M., Abdiche, Y. N., Lindquist, K. C., Farias, S. E., Rickert, M., Appah, C. T., Pascua, E., and Radcliffe, T. et al. 2012, Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair J. Mol. Biol. 420, 204-19 10.1016/j.jmb.2012.04.020
56. Barok, M., Tanner, M., Koninki, K., and Isola, J. (2011) Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo Breast Cancer Res. 13, R46 10.1186/bcr2868
57. de Goeij, B. E., Vink, T., Ten Napel, H., Breij, E. C., Satijn, D., Wubbolts, R., Miao, D., and Parren, P. W. (2016) Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63 Mol. Cancer Ther. 15, 2688 10.1158/1535-7163.MCT-16-0364
58. Chaparro-Riggers, J., Liang, H., DeVay, R. M., Bai, L., Sutton, J. E., Chen, W., Geng, T., Lindquist, K., Casas, M. G., and Boustany, L. M. et al. 2012, Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 J. Biol. Chem. 287, 11090-7 10.1074/jbc.M111.319764
59. Igawa, T., Ishii, S., Tachibana, T., Maeda, A., Higuchi, Y., Shimaoka, S., Moriyama, C., Watanabe, T., Takubo, R., and Doi, Y. et al. 2010, Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization Nat. Biotechnol. 28, 1203-7 10.1038/nbt.1691
60. Schroter, C., Gunther, R., Rhiel, L., Becker, S., Toleikis, L., Doerner, A., Becker, J., Schonemann, A., Nasu, D., and Neuteboom, B. et al. 2015, A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display MAbs 7, 138-51 10.4161/19420862.2014.985993
61. Jeger, S., Zimmermann, K., Blanc, A., Grunberg, J., Honer, M., Hunziker, P., Struthers, H., and Schibli, R. (2010) Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase Angew. Chem., Int. Ed. 49, 9995-7 10.1002/anie.201004243
62. Bravman, T., Bronner, V., Lavie, K., Notcovich, A., Papalia, G. A., and Myszka, D. G. (2006) Exploring ″one-shot″ kinetics and small molecule analysis using the ProteOn XPR36 array biosensor Anal. Biochem. 358, 281-8 10.1016/j.ab.2006.08.005
63. Myszka, D. G. (1999) Improving biosensor analysis J. Mol. Recognit. 12, 279-84 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3
64. Dunn, K. W., Kamocka, M. M., and McDonald, J. H. (2011) A practical guide to evaluating colocalization in biological microscopy Am. J. Physiol Cell Physiol 300, C723-42 10.1152/ajpcell.00462.2010
65. Pinilla-Macua, I. and Sorkin, A. (2015) Methods to study endocytic trafficking of the EGF receptor Methods Cell Biol. 130, 347-67 10.1016/bs.mcb.2015.05.008